Reversal of liver cirrhosis: current evidence and expectations
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
In the past, liver cirrhosis was considered an irreversible phenomenon. However, many experimental data have provided evidence of the reversibility of liver fibrosis. Moreover, multiple clinical studies have also shown regression of fibrosis and reversal of cirrhosis on repeated biopsy samples. As various etiologies are associated with liver fibrosis via integrated signaling pathways, a comprehensive understanding of the pathobiology of hepatic fibrogenesis is critical for improving clinical outcomes. Hepatic stellate cells play a central role in hepatic fibrogenesis upon their activation from a quiescent state. Collagen and other extracellular material components from activated hepatic stellate cells are deposited on, and damage, the liver parenchyma and vascular structures. Hence, inactivation of hepatic stellate cells can lead to enhancement of fibrolytic activity and could be a potential target of antifibrotic therapy. In this regard, continued efforts have been made to develop better treatments for underlying liver diseases and antifibrotic agents in multiple clinical and therapeutic trials; the best results may be expected with the integration of such evidence. In this article, we present the underlying mechanisms of fibrosis, current experimental and clinical evidence of the reversibility of liver fibrosis/cirrhosis, and new agents with therapeutic potential for liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 3×
“placebo RCT 247 Decreased fibrosis progression rate of PPAR-γ group (96-week F/U) [78]”
BackgroundMethodNeuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237 · cited 2×
“Recently, there has been a steady addition to the number of molecules and pathways that are targets for antifibrotic therapy (Table 3) [88,120-128]; TGF-β1 remains the most important of such molecules.”
BackgroundMethodSenescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788 · cited 3×
“In a more recent 5-year study with tenofovir treatment for chronic HBV infection that included patients with liver cirrhosis at the start of the study, 74% demonstrated extensive histological improvement, such that they were no longer considered to be cirrhotic [75].”
BackgroundMethodSelective depletion of macrophages reveals distinct, opposing roles during liver injury and repair
Duffield, J. S., Forbes, S. J., Constandinou, C. M., Clay, S., Partolina, M., Vuthoori, S., Wu, S., Lang, R., & Iredale, J. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522675 · Cited by 1,649 · cited 2×
“CCL2 and its receptor CCR2 are central to monocyte recruitment to the liver during hepatic inflammation and fibrosis [37,38].”
BackgroundRandomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance
Albillos, A., Lario, M., & Álvarez-Mon, M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.010 · Cited by 1,242 · cited 1×
“Pathogen-associated molecular patterns (PAMPs) from enteric bacterial organisms and damage-associated molecular patterns (DAMPs) originating from the host tissue upon injury stimulate innate immune cells [40].”
BackgroundLindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Iredale, J. P., Benyon, R. C., Pickering, J., McCullen, M., Northrop, M., Pawley, S., Hovell, C., & Arthur, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1018 · Cited by 1,075 · cited 3×
“Moreover, activated HSCs up-regulate the expression and synthesis of TIMP1 and TIMP2 [57].”
BackgroundMacrophage heterogeneity in liver injury and fibrosis
Tacke, F., & Zimmermann, H. W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.025 · Cited by 1,061 · cited 1×
“Furthermore, phagocytosis of apoptotic cells by macrophages induces MMP expression and augments ECM degradation in rodent models of resolving hepatocellular fibrosis [65].”
BackgroundMyofibroblasts revert to an inactive phenotype during regression of liver fibrosis
Kisseleva, T., Cong, M., Paik, Y., Scholten, D., Jiang, C., Benner, C., Iwaisako, K., Moore-Morris, T., Scott, B., Tsukamoto, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201840109 · Cited by 805
Aithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.047 · Cited by 721
Sterile inflammation in the liver
Kubes, P., & Mehal, W. Z. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.09.008 · Cited by 666 · cited 1×
“DAMPs and sterile particulates, also released from necrotic hepatocytes, might also contribute to elicit an inflammatory response and fibrosis [42].”
BackgroundHirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576 · cited 9×
“Obeticholic acid, a derivative of chenodeoxycholic acid, has, unlike UDCA, strong activating effects on the nuclear receptor farnesoid X receptor in phase II results [116].”
BackgroundMethodInfluentialDeactivation of Hepatic Stellate Cells During Liver Fibrosis Resolution in Mice
Troeger, J. S., Mederacke, I., Gwak, G., Dapito, D. H., Mu, X., Hsu, C. C., Pradere, J., Friedman, R. A., & Schwabe, R. F. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.036 · Cited by 515 · cited 1×
“This suggests that clearance of activated HSCs is a fundamental step in the onset of fibrosis regression [68].”
BackgroundHepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2
Miura, K., Yang, L., van Rooijen, N., Ohnishi, H., & Seki, E. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00365.2011 · Cited by 503 · cited 1×
“CCL2 and its receptor CCR2 are central to monocyte recruitment to the liver during hepatic inflammation and fibrosis [37,38].”
BackgroundUrsodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497 · cited 2×
“PBC UDCA RCT 146 No fibrosis improvement [89]”
BackgroundMethodFallowfield, J. A., Mizuno, M., Kendall, T. J., Constandinou, C. M., Benyon, R. C., Duffield, J. S., & Iredale, J. P. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.8.5288 · Cited by 479
Murphy, F. R., Issa, R., Zhou, X., Ratnarajah, S., Arthur, M. J. P., Benyon, C., Iredale, J. P., & Nagase, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111490200 · Cited by 432 · cited 1×
“TIMP1 not only prevents the degradation of the rapidly increasing ECM by blocking MMPs but also inhibits apoptosis of activated HSCs [58].”
BackgroundStaels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414 · cited 2×
“Recently, there has been a steady addition to the number of molecules and pathways that are targets for antifibrotic therapy (Table 3) [88,120-128]; TGF-β1 remains the most important of such molecules.”
BackgroundClinical evidence for the regression of liver fibrosis
Ellis, E. L., & Mann, D. A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.09.024 · Cited by 411 · cited 1×
“The serial assessment of biopsy samples from patients with chronic liver disease of diverse etiologies, who were successfully treated, indicates that liver fibrosis is a dynamic and bidirectional process that has an inherent capacity for recovery and remodeling [71].”
BackgroundThe role of TGFβ1 in initiating hepatic stellate cell activation in vivo
Hellerbrand, C., Stefanovic, B., Giordano, F., Burchardt, E. R., & Brenner, D. A. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80010-5 · Cited by 393
A role for autophagy during hepatic stellate cell activation
Thoen, L. F. R., Guimarães, E. L. M., Dollé, L., Mannaerts, I., Najimi, M., Sokal, E., & van Grunsven, L. A. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.07.010 · Cited by 385 · cited 1×
“Along with the switch from LD-rich cells to myofibroblast-like cells, autophagy flux is upregulated [45].”
BackgroundExpression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver
Benyon, R., Iredale, J., Goddard, S., Winwood, P., & Arthur, M. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8608892 · Cited by 353 · cited 1×
“Activated HSCs not only synthesize and secrete ECM proteins such as type I and type III collagen but also produce MMP1 and MMP13 [56].”
BackgroundA randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
Ratziu, V., de Ledinghen, V., Oberti, F., Mathurin, P., Wartelle-Bladou, C., Renou, C., Sogni, P., Maynard, M., Larrey, D., Serfaty, L., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.030 · Cited by 338
Iredale, J. P., Benyon, R. C., Arthur, M. J., Ferris, W. F., Alcolado, R., Winwood, P. J., Clark, N., & Murphy, G. (1996) · Hepatology · doi:10.1002/hep.510240129 · Cited by 324 · cited 3×
“Leptin, which is a circulating adipogenic hormone, promotes stellate cell fibrogenesis, enhances tissue inhibitor of metalloproteinase 1 (TIMP-1) expression, exerts its action through Janus kinase (JAK)-signal transduction, and suppresses peroxisome proliferator-activated receptor γ (PPAR-γ) [18].”
BackgroundCorpechot, C., Carrat, F., Bonnand, A.-M., Poupon, R. E., & Poupon, R. (2000) · Hepatology · doi:10.1053/jhep.2000.20240 · Cited by 316 · cited 1×
“Next, we will describe the evidence and research outcomes of liver fibrosis recovery in clinical practice settings according to different etiologies (Tables 1 and 2) [72-90].”
MethodGoulis, J., Leandro, G., & Burroughs, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11293-x · Cited by 315 · cited 7×
“Obeticholic acid, a derivative of chenodeoxycholic acid, has, unlike UDCA, strong activating effects on the nuclear receptor farnesoid X receptor in phase II results [116].”
BackgroundInfluentialZhan, S.-S., Jiang, J. X., Wu, J., Halsted, C., Friedman, S. L., Zern, M. A., & Torok, N. J. (2006) · Hepatology · doi:10.1002/hep.21093 · Cited by 284 · cited 1×
“The production of ROS is influenced by the activity of NADPH oxidase in HSCs, macrophages, and hepatocytes and by the production of nitric oxide in Kupffer cells [10-12].”
BackgroundPrince, M. I., Chetwynd, A., Craig, W. L., Metcalf, J. V., & James, O. F. W. (2004) · Gut · doi:10.1136/gut.2003.023937 · Cited by 261 · cited 1×
“[114], 45% of the patients taking UDCA did not develop liver-related symptoms during a median follow-up of 7.”
BackgroundHuman Hepatic Stellate Cells Express CCR5 and RANTES to Induce Proliferation and Migration
Schwabe, R. F., Bataller, R., & Brenner, D. A. (2003) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00215.2003 · Cited by 252 · cited 1×
“In turn, HSCs respond to this stimulation by secreting macrophage colony-stimulating factor, MCP-1, interleukin 6 (IL-6), C-C motif chemokine ligand type 21 (CCL21), and C-C motif chemokine receptor type 5 (CCR5) leading to an amplified acute phase response with further activation of macrophages [23-25].”
BackgroundJiang, J. X., Chen, X., Serizawa, N., Szyndralewiez, C., Page, P., Schröder, K., Brandes, R. P., Devaraj, S., & Török, N. J. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.05.007 · Cited by 251 · cited 2×
“NOX4 can trigger apoptosis in hepatocytes [27,124].”
BackgroundMesenchymal stem cell therapy for liver fibrosis
Eom, Y. W., Shim, K. Y., & Baik, S. K. (2015) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.30.5.580 · Cited by 226 · cited 1×
“MSCs have the potential to differentiate into hepatocytes and their therapeutic value lies in their immune-modulatory properties and secretion of trophic factors, such as growth factors and cytokines [132].”
BackgroundDendritic Cell Regulation of Carbon Tetrachloride–Induced Murine Liver Fibrosis Regression
Jiao, J., Sastre, D., Fiel, M. I., Lee, U. E., Ghiassi–Nejad, Z., Ginhoux, F., Vivier, E., Friedman, S. L., Merad, M., & Aloman, C. (2012) · Hepatology · doi:10.1002/hep.24621 · Cited by 154
Weng, H., Mertens, P. R., Gressner, A. M., & Dooley, S. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2006.09.014 · Cited by 152
Jeong, W.-I., Park, O., Suh, Y.-G., Byun, J.-S., Park, S.-Y., Choi, E., Kim, J.-K., Ko, H., Wang, H., Miller, A. M., et al. (2011) · Hepatology · doi:10.1002/hep.24190 · Cited by 142
Amelioration of hepatic fibrosis by NK cell activation
Muhanna, N., Tair, L. A., Doron, S., Amer, J., Azzeh, M., Mahamid, M., Friedman, S., & Safadi, R. (2011) · Gut · doi:10.1136/gut.2010.211136 · Cited by 127 · cited 3×
“In turn, HSCs respond to this stimulation by secreting macrophage colony-stimulating factor, MCP-1, interleukin 6 (IL-6), C-C motif chemokine ligand type 21 (CCL21), and C-C motif chemokine receptor type 5 (CCR5) leading to an amplified acute phase response with further activation of macrophages [23-25].”
BackgroundKaplan, M. M., Cheng, S., Price, L. L., & Bonis, P. A. L. (2004) · Hepatology · doi:10.1002/hep.20103 · Cited by 87 · cited 1×
“A few studies evaluating methotrexate have presented conflicting results and some studies suggest that methotrexate may worsen mortality [115].”
Result
Cited by
Fibrosis and alcohol-related liver disease
Lackner, C., & Tiniakos, D. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.12.003 · Cited by 322
Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression
Caligiuri, A., Gentilini, A., Pastore, M., Gitto, S., & Marra, F. (2021) · Cells · doi:10.3390/cells10102759 · Cited by 270
Hepatic fibrosis: It is time to go with hepatic stellate cell-specific therapeutic targets
Ezhilarasan, D., Sokal, E., & Najimi, M. (2018) · Hepatobiliary & Pancreatic Diseases International · doi:10.1016/j.hbpd.2018.04.003 · Cited by 204
Integrins as a drug target in liver fibrosis
Rahman, S. R., Roper, J. A., Grove, J. I., Aithal, G. P., Pun, K. T., & Bennett, A. J. (2022) · Liver International · doi:10.1111/liv.15157 · Cited by 74
The Space of Disse: The Liver Hub in Health and Disease
Sanz-García, C., Fernández-Iglesias, A., Gracia-Sancho, J., Arráez-Aybar, L. A., Nevzorova, Y. A., & Cubero, F. J. (2021) · Livers · doi:10.3390/livers1010002 · Cited by 57
“However, advanced fibrosis can progress into more severe stages, like cirrhosis, with irreversible damage to the liver and end-stage HCC [4,9,75].”
BackgroundInfluential
Metadata
- Authors
- Jung, Y. K., & Yim, H. J.
- Venue
- The Korean Journal of Internal Medicine
- Published
- 2017-03-01
- Volume
- 32
- Issue
- 2
- Pages
- 213-228
- ISSN
- 1226-3303 (ISSN-L)
- 2005-6648
- OpenAlex
- W2587500246
- Cited by
- 148
- References
- 40
- FWCI
- 7.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.